Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Aris P Agouridis, Vasilis Tsimihodimos, Theodosios D Filippatos, Andromachi A Dimitriou, Costantinos C Tellis, Moses S Elisaf, Dimitri P Mikhailidis & Alexandros D Tselepis. (2011) The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opinion on Pharmacotherapy 12:17, pages 2605-2611.
Read now
Read now
Jean-Pierre Déry. (2011) Controlling lipids after acute coronary syndromes: what is the best strategy?. Clinical Lipidology 6:3, pages 253-255.
Read now
Read now
Feray Kockar, Selma Sinan, Hatice Yildirim & Oktay Arslan. (2010) Differential effects of some antibiotics on paraoxonase enzyme activity on human hepatoma cells (HepG2) in vitro. Journal of Enzyme Inhibition and Medicinal Chemistry 25:5, pages 715-719.
Read now
Read now
Ioannis K. Karalis, Sandrin C. Bergheanu, Ron Wolterbeek, Geesje M. Dallinga-Thie, Hiroaki Hattori, Arie van Tol, Anho H. Liem & J. Wouter Jukema. (2010) Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Current Medical Research and Opinion 26:10, pages 2301-2313.
Read now
Read now
Sandrin C. Bergheanu, Theo Reijmers, Aeilko H. Zwinderman, Ivana Bobeldijk, Raymond Ramaker, An-Ho Liem, Jan van der Greef, Thomas Hankemeier & J. Wouter Jukema. (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Current Medical Research and Opinion 24:9, pages 2477-2487.
Read now
Read now
Maureen McMahon & Ernest Brahn. (2008) Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opinion on Investigational Drugs 17:8, pages 1213-1224.
Read now
Read now
Articles from other publishers (26)
Myriam Jaam, Hend Nasser Al-Naimi, Moumena Mahmoud Haddad, Dina Abushanab & Daoud Al-Badriyeh. (2023) Comparative efficacy and safety among high-intensity statins. Systematic Review and Meta-Analysis. Journal of Comparative Effectiveness Research 12:3.
Crossref
Crossref
Qi Zhang, Zongzhe Jiang & Yong Xu. 2022. HDL Metabolism and Diseases. HDL Metabolism and Diseases
63
77
.
Aysun Çetin, İhsan Çetin, Semih Yılmaz, Ahmet Şen, Göktuğ Savaş, Behzat Çimen & Ahmet Öztürk. (2019) Oxydative stress markers and cytokine levels in rosuvastatin-medicated hypercholesterolemia patients. Turkish Journal of Biochemistry 44:4, pages 530-538.
Crossref
Crossref
Mathijs C. Bodde, Paul Welsh, Sandrin C. Bergheanu, Willem M. Lijfering, Bart Mertens, An-Ho Liem, Arnoud van der Laarse, Naveed Sattar & J. Wouter Jukema. (2018) A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular Disease. Clinical Pharmacology & Therapeutics 104:2, pages 311-316.
Crossref
Crossref
Fernando Brites, Maximiliano Martin, Isabelle Guillas & Anatol Kontush. (2017) Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit. BBA Clinical 8, pages 66-77.
Crossref
Crossref
N. Ponce-Ruiz, F.E. Murillo-González, A.E. Rojas-García, Mike Mackness, Y.Y. Bernal-Hernández, B.S. Barrón-Vivanco, C.A. González-Arias & I.M. Medina-Díaz. (2017) Transcriptional regulation of human Paraoxonase 1 by nuclear receptors. Chemico-Biological Interactions 268, pages 77-84.
Crossref
Crossref
Sunghwan SuhChang Hee JungSoon-Jun HongJung-Sun KimByung Ju SongHyun Soon SohnSung Hee Choi. (2016) Economic Evaluation of Rosuvastatin and Atorvastatin for the Treatment of Dyslipidemia from a Korean Health System Perspective. Journal of Lipid and Atherosclerosis 5:1, pages 61.
Crossref
Crossref
Rafał Januszek. (2016) Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease. International Journal of Vascular Medicine 2016, pages 1-10.
Crossref
Crossref
Gianna Ferretti, Tiziana Bacchetti & Amirhossein Sahebkar. (2015) Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Progress in Lipid Research 60, pages 50-73.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. (2015) Atorvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Monica Gomaraschi, Maria Pia Adorni, Maciej Banach, Franco Bernini, Guido Franceschini & Laura Calabresi. 2015. High Density Lipoproteins. High Density Lipoproteins
593
615
.
Zhi-Hua Lv, Pei Ma, Wan Luo, Hui Xiong, Lu Han, Si-Wei Li, Xin Zhou & Jian-Cheng Tu. (2014) Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction. BMC Cardiovascular Disorders 14:1.
Crossref
Crossref
Stephen P Adams, Sarpreet S Sekhon & James M Wright. (2014) Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews 2017:1.
Crossref
Crossref
Jan Willem Cohen Tervaert. (2013) Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Practice & Research Clinical Rheumatology 27:1, pages 33-44.
Crossref
Crossref
Stephen P Adams, Michael Tsang & James M Wright. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Jan Willem Cohen Tervaert. 2012. Inflammatory Diseases of Blood Vessels. Inflammatory Diseases of Blood Vessels
473
483
.
Jordi Camps, Anabel García-Heredia, Anna Rull, Carlos Alonso-Villaverde, Gerard Aragonès, Raúl Beltrán-Debón, Esther Rodríguez-Gallego & Jorge Joven. (2012) PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways. PPAR Research 2012, pages 1-10.
Crossref
Crossref
Shizuya Yamashita, Kazumi Tsubakio-Yamamoto, Tohru Ohama, Yumiko Nakagawa-Toyama & Makoto Nishida. (2010) Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions. Journal of Atherosclerosis and Thrombosis 17:5, pages 436-451.
Crossref
Crossref
Mariann Harangi, Ildikó Seres, János Harangi & György Paragh. (2009) Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment. Cardiovascular Drugs and Therapy 23:6, pages 501-510.
Crossref
Crossref
Jakub J. Regieli, J. Wouter Jukema, Pieter A. Doevendans, Aeilko H. Zwinderman, John J. Kastelein, Diederick E. Grobbee & Yolanda van der Graaf. (2009) Paraoxonase Variants Relate to 10-Year Risk in Coronary Artery Disease. Journal of the American College of Cardiology 54:14, pages 1238-1245.
Crossref
Crossref
Sevil KurbanIdris Mehmetoglu & Erdal Ege. (2009) Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting. Perfusion 24:4, pages 271-276.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Theodosios D. Filippatos, Leonidas G. Christogiannis, Eleni T. Bairaktari, Alexandros D. Tselepis & Moses S. Elisaf. (2009) Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:1, pages 5-13.
Crossref
Crossref
R. P. F. Dullaart, R. de Vries, H. A. M. Voorbij, W. J. Sluiter & A. van Tol. (2009) Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. European Journal of Clinical Investigation 39:3, pages 200-203.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis & Moses S. Elisaf. (2008) An Overview of the Extra-Lipid Effects of Rosuvastatin. Journal of Cardiovascular Pharmacology and Therapeutics 13:3, pages 157-174.
Crossref
Crossref
Ran Fu, Yan-Ming Sun, Ying Su, Yun Wu & Ying Luan. (2008) EFFECT OF STATIN THERAPY ON PLASMA HIGH-DENSITY LIPOPROTEINCHOLESTEROL LEVELS IS MODIFIED BY PARAOXONASE 1 IN CHINESE PATIENTS WITH CORONARY HEART DISEASE. Clinical and Experimental Pharmacology and Physiology 35:8, pages 982-983.
Crossref
Crossref
Gillian M. Keating & Dean M. Robinson. (2012) Rosuvastatin. American Journal of Cardiovascular Drugs 8:2, pages 127-146.
Crossref
Crossref